Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.
Lombardi P, Kim JS, Manfredi GF, Celsa C, Fulgenzi CAM, D'Alessio A, Stefanini B, Doshi NC, Warmington E, Marron TU, Pinter M, Scheiner B, Kang B, Lim HY, Hsu WF, Wietharn B, Silletta M, Parisi A, Lin CY, Dalbeni A, Masi G, Schönlein M, von Felden J, Piscaglia F, Galle PR, Kudo M, Pressiani T, Rimassa L, Pirisi M, Cabibbo G, Chon HJ, Pinato DJ.
Lombardi P, et al. Among authors: lim hy.
JHEP Rep. 2025 Sep 23;7(12):101595. doi: 10.1016/j.jhepr.2025.101595. eCollection 2025 Dec.
JHEP Rep. 2025.
PMID: 41321927
Free PMC article.